The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure (Q38012491)

27 August 2017

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure (English)

1 reference

27 August 2017

Sze Wa Chan

1

1 reference

27 August 2017

Miao Hu

series ordinal

2

1 reference

27 August 2017

Brian Tomlinson

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 May 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

27 August 2017

1 reference

27 August 2017

8

1 reference

27 August 2017

7

1 reference

27 August 2017

767-790

1 reference

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The role of β-blockers in the management of hypertension: an Asian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Does atenolol differ from other beta-adrenergic blockers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Variability in response to antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Use of beta-adrenergic receptor blockers in blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Why is plasma renin activity lower in populations of African origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Ethnic differences in response to beta-blockade: fact or artefact? A study with bisoprolol and propranolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)-propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta-adrenoceptors in cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Adrenergic signaling polymorphisms and their impact on cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Are we misunderstanding beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Sympatholytic therapy in primary hypertension: a user friendly role for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Presence of a Serum Vasoconstrictive Factor Following Unilateral Nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Cardiovascular drug class specificity: beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Lack of evidence that nebivolol is a β₃-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Variability in response to cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Cardiovascular drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Atenolol interaction with aspirin, allopurinol, and ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Pharmacogenetics: from bench to byte--an update of guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Pharmacogenetics of beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

β2 -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genome-wide association studies of hypertension: have they been fruitful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genome-wide association study of blood pressure and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genome-wide association study identifies eight loci associated with blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

β(1)-adrenergic receptor polymorphisms and response to β-blockade in the African-American study of kidney disease and hypertension (AASK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Clinical and genetic modifiers of long-term survival in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Distributive characteristics of Ser49Gly and Gly389Arg genetic polymorphisms of beta1-adrenoceptor in Chinese Han and Dai populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Insertion/insertion genotype of α(2B)-adrenergic receptor gene polymorphism is associated with silent myocardial ischemia in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein beta3 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

The Trp64Arg polymorphism of the β3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.685157

10.1517/17425255.2012.685157

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference